Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
03 Juin 2024 - 7:05PM
Business Wire
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr.
Reddy’s Laboratories Limited company, inaugurated its biologics
facility spread across 70,000 sq.ft. in Genome Valley, a bio
cluster, located in Hyderabad, India. The facility is designed to
serve customers with process & analytical development and small
scale manufacturing of antibodies and other recombinant proteins
for preclinical and early phase clinical requirements. The process
and analytical development laboratories are now operational while
the commissioning of manufacturing capacity will be completed later
in 2024.
The state-of-the-art facility is equipped with best-in-class
equipment and control systems, supported by an experienced talent
pool that will ensure seamless transfer to large-scale commercial
CGMP manufacturing facilities. The new facility is complementary to
the company’s current discovery capabilities and infrastructure,
which primarily focuses on recombinant proteins including mAbs, bi-
and multi-specifics, immune-fusion molecules, antibody drug
conjugates and other complex proteins.
Aurigene’s comprehensive end-to-end service offering now
delivers solutions from, discovery through large-scale commercial
manufacturing from three proximally located campuses (discovery,
process development/clinical manufacture and large scale commercial
manufacture) thus ensuring seamless delivery from “concept to
commercial”. The newly opened Genome Valley facility will deliver
robust, compliant and economically viable cell lines, process
development solutions and supporting analytical methods in support
of customers seeking to rapidly enter and progress through clinical
development.
The opening of this latest facility is one of multiple strategic
initiatives that Aurigene is implementing to support rapid growth
in both the small molecule and biologics spaces, as illustrated by
recent announcements related to AI/ML-led drug discovery in small
molecules and a collaboration with Vipergen, a DNA-encoded library
(DEL) technologies service provider.
Akhil Ravi, CEO, Aurigene, commented, “The journey
started a year back when we decided to invest in creating the
facility. It is great to see the facility operational and the
addition of this capacity and capabilities shows our firm
commitment to the continued expansion of our biologics business,
building on 25 years of proven experience. The state-of-the-art
facility will enable us to service our global customers efficiently
and support in the development of innovative medicine.”
Dr. Roger Lias, Global Commercial Head – Biologics, Aurigene,
added, “There are very few global CDMOs that can truly support
customers ‘end-to-end’ from discovery services to large scale
commercial manufacture of both Drug Substance and Drug Product. Our
new facility further strengthens Aurigene’s capabilities and builds
on our technical excellence, demonstrated global compliance and
state-of-the-art facilities as companies from start-up biotechs to
global multinationals continue to strengthen their supply chains
and seek economically viable support for both their development
portfolios and marketed products.”
About Aurigene:
Aurigene is a global contract research, development, and
manufacturing organization (CRDMO) – a Dr. Reddy’s company – built
on the legacy of accelerating innovation and backed by a vast
experience in drug discovery, development, and manufacturing of
biologics and small molecules. Aurigene offers integrated and
standalone services for biotherapeutics discovery, discovery
chemistry, discovery biology, development and manufacturing
services for clinical phase I-III programs, regulatory submission
batches and commercial manufacturing.
For more information log on to:
https://www.aurigeneservices.com/ or email us at:
ContactAPSL@aurigeneservices.com LinkedIn YouTube
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global
pharmaceutical company headquartered in Hyderabad, India.
Established in 1984, we are committed to providing access to
affordable and innovative medicines. Driven by our purpose of ‘Good
Health Can’t Wait’, we offer a portfolio of products and services
including APIs, generics, branded generics, biosimilars and OTC.
Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and
dermatology. Our major markets include – USA, India, Russia &
CIS countries, China, Brazil, and Europe. As a company with a
history of deep science that has led to several industry firsts, we
continue to plan and invest in businesses of the future. As an
early adopter of sustainability and ESG actions, we released our
first Sustainability Report in 2004. Our current ESG goals aim to
set the bar high in environmental stewardship; access and
affordability for patients; diversity; and governance.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240603193491/en/
Usha Iyer Head of Corporate Communications
ushaiyer@drreddys.com
Richa Periwal Head of Investor Relations
richaperiwal@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Dr Reddys Laboratories (NYSE:RDY)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024